Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
2019
2019
Verdox is developing technology for reversing climate change via electrochemical carbon capture
2019
2019
Pillar VC is a Boston venture capital firm that supports founders with early-stage and seed VC funding, investing in their professional & personal growth.
2019
2019
Petri develops companies attacking the world’s largest problems at the frontier of biology and engineering.
2009 - 2021
2009 - 2021
Midori is pioneering a novel category of products that modulate the animal microbiome to improve health and nutrition. For the production industry, our technology improves the economics, quality, and sustainability of animal protein without resorting to widespread use of antibiotics and other drugs. For companion animals, it promises better health, nutrition, and quality of life. Midori was sold to Royal DSM (AMS:DSM) in 2017.
2015 - 2018
2015 - 2018
Kaleido Biosciences is a clinical-stage biotechnology company engaged in the development of novel chemistries that unlock the power of the microbiome to revolutionize health. The Company has built the first R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health. Kaleido has advanced candidate products into clinical studies across programs in rare genetic diseases, oncology and infectious disease, and has generated more than 3,000 days of human clinical data. The Company is also creating consumer products that optimize the microbiome's natural roles in promoting health. Kaleido had an IPO on the Nasdaq in early 2019.
2009 - 2017
2009 - 2017
Flagship Pioneering conceives, creates, resources and develops first-in-category life sciences companies. Its institutional innovation foundry, Flagship VentureLabs®, is where Flagship's team of scientific entrepreneurs systematically evolve enterprising ideas into new fields, or previously undiscovered areas of science into real-world inventions and ventures. Since its launch in 2000, the firm has applied its hypothesis-driven innovation process to originate and foster nearly 75 scientific ventures, resulting in $19 billion in aggregate value, 500+ issued patents and more than 50 clinical trials for novel therapeutic agents. Flagship's portfolio includes pioneering ventures that are transforming human health and sustainability, including: Agios Pharmaceuticals (NASDAQ: AGIO), Seres Therapeutics (NASDAQ: MCRB), Editas Medicine (NASDAQ: EDIT) and Syros Pharmaceuticals (NASDAQ: SYRS), as well as private companies including Moderna Therapeutics, Indigo Agriculture and Axcella Health. Flagship has ongoing corporate innovation alliances with several market leaders, including: AstraZeneca, Bayer Crop Science and Nestlé Health Science.
2009 - 2015
2009 - 2015
CELEXION is a bioengineering company that develops platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. The company’s technologies include the SECANT platform for engineering high performance protein products, a library of human antibodies for therapeutic lead generation, enzymatic pathways for synthesis of a variety of high-value renewable chemicals and materials from wastes and other inexpensive precursors, and a novel family of enzymes for manipulation of chromosome-sized DNA. Celexion was sold to Agenus (NASDAQ:AGEN) in 2015.
2004 - 2009
2004 - 2009
Codon Devices focused on enabling commercial applications of synthetic biology. Codon Devices' proprietary synthesis and design technologies improve the productivity, throughput and flexibility of its industrial, pharmaceutical and academic customers in a paradigm shift to what the company calls Constructive Biology(TM). The company's focus is on developing and delivering high-value products and design services in a variety of application areas, including engineered gene libraries, engineered cells that produce novel pharmaceuticals, improved vaccines, agricultural products, and biorefineries for the production of industrial chemicals and energy. Codon Devices' BioFAB(TM) platform uses sophisticated informatics, robotics and sequencing technologies to accurately synthesize genetic codes orders of magnitude more rapidly and cost-effectively than other currently available technology. Codon Devices is currently scaling the platform to design and construct engineered genetic devices hundreds of kilobases to megabases in length. Codon Devices was sold to Gen9 (now Ginkgo Bioworks, NYSE:DNA) in 2009.
1996 - 2001
1996 - 2001